◎ Sugi Atlas

Atlas / Gene / HSD3B1

HSD3B1

gene
On this page

Also known as SDR11E1

Summary

HSD3B1 (hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1, HGNC:5217) is a protein-coding gene on chromosome 1p12, encoding 3 beta-hydroxysteroid dehydrogenase/Delta 5–>4-isomerase type 1 (P14060). A bifunctional enzyme responsible for the oxidation and isomerization of 3beta-hydroxy-Delta(5)-steroid precursors to 3-oxo-Delta(4)-steroids, an essential step in steroid hormone biosynthesis.

The protein encoded by this gene is an enzyme that catalyzes the oxidative conversion of delta-5-3-beta-hydroxysteroid precursors into delta-4-ketosteroids, which leads to the production of all classes of steroid hormones. The encoded protein also catalyzes the interconversion of 3-beta-hydroxy- and 3-keto-5-alpha-androstane steroids.

Source: NCBI Gene 3283 — RefSeq curated summary.

At a glance

  • GWAS associations: 1
  • Clinical variants (ClinVar): 74 total
  • Druggable target: yes — 1 molecules with ChEMBL bioactivity
  • MANE Select transcript: NM_000862

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:5217
Approved symbolHSD3B1
Namehydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1
Location1p12
Locus typegene with protein product
StatusApproved
AliasesSDR11E1
Ensembl geneENSG00000203857
Ensembl biotypeprotein_coding
OMIM109715
Entrez3283

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 protein_coding, 2 retained_intron

ENST00000369413, ENST00000487520, ENST00000492140, ENST00000528909, ENST00000531340

RefSeq mRNA: 2 — MANE Select: NM_000862 NM_000862, NM_001328615

CCDS: CCDS903

Canonical transcript exons

ENST00000369413 — 4 exons

ExonStartEnd
ENSE00001201506119507210119507262
ENSE00001722296119511503119511667
ENSE00001846945119513834119515054
ENSE00003667298119507392119507621

Expression profiles

Bgee: expression breadth ubiquitous, 154 present calls, max score 96.87.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 2.6541 / max 1178.4454, expressed in 51 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter IDTPM avgSamples expressed
49222.436948
49210.217222

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
placentaUBERON:000198796.87gold quality
deciduaUBERON:000245094.88gold quality
upper leg skinUBERON:000426294.25gold quality
mammalian vulvaUBERON:000099784.75gold quality
small intestine Peyer’s patchUBERON:000345470.74gold quality
right adrenal gland cortexUBERON:003582768.73gold quality
right adrenal glandUBERON:000123367.94gold quality
left adrenal glandUBERON:000123466.65gold quality
left adrenal gland cortexUBERON:003582566.14gold quality
mucosa of transverse colonUBERON:000499166.08gold quality
ileal mucosaUBERON:000033165.40silver quality
small intestineUBERON:000210864.98gold quality
adrenal cortexUBERON:000123564.84gold quality
islet of LangerhansUBERON:000000663.54gold quality
adrenal glandUBERON:000236963.14gold quality
monocyteCL:000057661.59gold quality
mononuclear cellCL:000084261.43gold quality
cranial nerve IIUBERON:000094159.91silver quality
right lungUBERON:000216759.43gold quality
leukocyteCL:000073859.38gold quality
nippleUBERON:000203058.73gold quality
omental fat padUBERON:001041458.31gold quality
peritoneumUBERON:000235858.26gold quality
adipose tissue of abdominal regionUBERON:000780857.34gold quality
buccal mucosa cellCL:000233657.12silver quality
right coronary arteryUBERON:000162556.76gold quality
tibialis anteriorUBERON:000138555.86silver quality
skin of abdomenUBERON:000141655.66gold quality
zone of skinUBERON:000001455.17gold quality
smooth muscle tissueUBERON:000113554.68gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

ExperimentMarker?Max mean expression
E-MTAB-6701yes1654.38
E-MTAB-6678yes6.73
E-ANND-3no2.12

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR, DLX3, ESR1, NR0B1, NR4A2, NR5A1, SP1, STAT5A, TFAP2C, YY1

miRNA regulators (miRDB)

20 targeting HSD3B1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNAMax scoreAvg scoremiRNA target_count
HSA-MIR-4262100.0073.263931
HSA-MIR-181A-5P99.9972.962995
HSA-MIR-181B-5P99.9972.972996
HSA-MIR-181C-5P99.9972.952996
HSA-MIR-181D-5P99.9973.042997
HSA-MIR-472999.6972.184233
HSA-MIR-6758-3P99.5767.551078
HSA-MIR-54399.5269.032595
HSA-MIR-391599.4568.491905
HSA-MIR-569099.2567.581012
HSA-MIR-3124-3P98.8768.952123
HSA-MIR-314998.7767.131639
HSA-MIR-6780A-3P98.4267.491518
HSA-MIR-5681A97.9967.171658
HSA-MIR-3187-3P97.3865.80904
HSA-MIR-2114-5P96.0064.56617
HSA-MIR-4774-5P95.9268.27827
HSA-MIR-6874-5P95.7364.94545
HSA-MIR-4633-3P93.8563.56534
HSA-MIR-6500-5P93.8563.64522

Literature-anchored findings (GeneRIF, showing 40)

  • nonstop mutation in the stop codon and missense mutation in type II 3beta-hydroxysteroid dehydrogenase gene causing 3beta-HSD deficiency congenital adrenal hyperplasia. (PMID:12050213)
  • Polymorphism in exon 4 of the human gene and blood presssure (PMID:12054649)
  • Structure/function relationships responsible for the kinetic differences between isoforms (PMID:12205101)
  • HSD3B1 was identified using a trifunctional phenyl sulfonate probe. (PMID:12438565)
  • Substantially higher affinity of 3beta-HSD1 activity for substrate and inhibitor steroids relative to the 3beta-HSD2 enzyme. (PMID:12530651)
  • In outer region of adrenal cortex immunoreactivity was observed for 3beta-hydroxysteroid dehydrogenase. (PMID:12530676)
  • Structure/function relationships responsible for coenzyme specificity and the isomerase activity of this multienzyme complex. (PMID:12832414)
  • Descending HSD3B phenotype in hyperandrogenic females is associated with a variant of insulin-resistant polycystic ovary syndrome. (PMID:14764797)
  • Neither of the HSD3B1 or PTP1B variants were associated with hypertension (PMID:15097232)
  • results designate YY1 as the factor responsible for the intron 1-mediated boost of the HSD3B2 gene basal promoter activity (PMID:15291746)
  • further characterizes structure/function relationships of human 3beta-HSD and bring us closer to the goal of selectively inhibiting the type 1 enzyme in placenta to control the timing of labor or in hormone-sensitive breast tumors to slow their growth (PMID:15291757)
  • identification of structural reasons for the substantially higher affinities of 3beta-HSD1 for substrates, coenzymes, and inhibitors (PMID:15797861)
  • The Rossmann-fold domain of 3beta-HSD1 contains two Cys residues, Cys72 and Cys111, which are capable of forming an intrasubunit disulfide bond based on their proximity in our structural model. (PMID:17624763)
  • Variant in the HSD3B1 gene is associated with increased mammographic density (PMID:17627014)
  • There is a possible role in human disease of common genetic variation in HSD3B1 and HSD3B2. (PMID:17689071)
  • results suggest that the HSD3B1 N367T and UGT2B17 null polymorphisms may modify the risk of prostate cancer, particularly among men with a family history of the disease (PMID:17826523)
  • HSD3B1 is highly specific and sensitive compared with other trophoblastic markers dor differential diagnosis of trophoblastic tumors and tumorlike lesions.. (PMID:18223326)
  • Structure/function of the inhibition of HSD3B1 by trilostane is reported. (PMID:18524572)
  • The activity levels of 17beta-hydroxysteroid dehydrogenase (17beta-HSD), 3beta-hydroxysteroid dehydrogenase (3beta-HSD), 3alpha-hydroxysteroid dehydrogenase (3alpha-HSD/3-KSR) and estrone sulfatase in ovarian epithelial carcinomas, were assayed. (PMID:18723074)
  • Anti-inflammatory effects of IL-1alpha and IL-4 on 3beta-HSD2 mRNA involve a p38 MAPK signalling pathway, whereas pro-inflammatory response of IL-1alpha to 3beta-HSD1 mRNA involves a NF-kappaB inflammatory pathway. (PMID:18778748)
  • The high affinity, competitive inhibition of 3beta-HSD1 by trilostane and epostane may be related to the presence of Arg195 in 3beta-HSD1 vs. Pro195 in 3beta-HSD2. (PMID:18955108)
  • The genetic polymorphisms of the HSD3B1,genes were found to be significantly different (p<0.05) between the uremic and non-uremic diabetes group (PMID:19148546)
  • Among patients with essential hypertension, cholesterol side-chain cleavage & MDR1 loci are related to circulating endogenous ouabain & DBP. In contrast, variants in HSD3B1 are related with SBP probably via aldosterone (PMID:19197249)
  • 3beta-HSD protein was immunodetectable in primary ascites of women who were diagnosed with epithelial ovarian cancer but mRNA transcripts of both 3beta-hydroxysteroid dehydrogenase type 1 and type 2 were diminished relative to normal cells. (PMID:19414525)
  • compared (+)- and (-)-gossypols in the inhibition of 3beta-HSD and 17beta-HSD3 in human and rat testes (PMID:19429456)
  • We investigated associations between single nucleotide polymorphisms in genes HSD3B1, SRD5A1/2, and AKR1C2 and prostate cancer risk (PMID:20056642)
  • Data indicate that enzymes CYP17A1 and HSD3B1 showed low expression, while AKR1C3 and SRD5A1 were abundantly expressed. (PMID:20086173)
  • The study identifies an amino acid in the steroid binding domain of human 3-beta-HSD I that may be exploited to produce new inhibitors that are much more highly specific for 3-beta-HSD I in breast tumors compared to adrenal 3-beta-HSD II. (PMID:20420909)
  • rs6203 and rs1047303 in the HSD3B1 gene are useful genetic markers for essential hypertension, while polymorphisms of HSD3B1 are associated with the BP and aldosterone level. (PMID:20660004)
  • The HSD3B1 T/C polymorphism cannot be used as genetic marker for the risk for recurrent spontaneous abortions in our Caucasian population. (PMID:21631238)
  • There is expression of 3beta-Hsd1 in XX gonads during gonad differentiation period. (PMID:21932034)
  • The aim of this haplotype-based case-control study was to estimate whether polymorphisms of the maternal estrogen synthesis genes (CYP19A1, HSD3B1 and HSD3B2) are associated with preeclampsia and gestational hypertension (PMID:22638611)
  • Carriers of HSD3B1 GCC haplotype had lower peak early (Ea; P = 0.004) and higher peak late (Aa; P = 0.066) diastolic mitral annular velocities and therefore a lower Ea/Aa ratio (P = 0.041) as compared with noncarriers (PMID:22673022)
  • elevated in placental tissue of women with polycystic ovarian syndrome (PMID:23122578)
  • HSD3B1 is a highly specific trophoblast-associated marker that can be used in the distinction of trophoblastic tumorlike lesions and tumors from nontrophoblastic lesions and tumors. (PMID:23318910)
  • HSD3B1 T–>C Leu338, HTR2A T102C, GNAS T393C, and RGS2 G638A polymorphisms were not associated with hypertension risk. (PMID:23859711)
  • Study shows that castration-resistant prostate cancer sometimes expresses a gain-of-stability mutation that leads to a gain-of-function in 3betaHSD1, which catalyzes the initial rate-limiting step in conversion of the adrenal-derived steroid dehydroepiandrosterone to dihydrotestosterone. (PMID:23993097)
  • Risk-conferring genetic variations in the HSD3beta gene influenced susceptibility of primary aldosteronism. Concomitant presence of rs6203 CC and rs12410453 GA genotypes synergistically increased aldosterone-to-renin ratio (PMID:24006038)
  • The AAT haplotype of the HSD3B1 gene was significantly associated with increased risks of acne vulgaris in Han Chinese from the Southwest China. (PMID:24157973)
  • Expression of the genes HSD3B1, HSD17B3, and SRD5A2 was significantly increased in BPH tissues compared to normal adjacent prostate tissues. (PMID:24810473)

Cross-species orthologs

17 orthologs

OrganismSymbolGene ID
danio_reriotdh2ENSDARG00000001463
danio_reriohsd3b2ENSDARG00000019747
danio_reriohsd3b1ENSDARG00000069926
mus_musculusHsd3b6ENSMUSG00000027869
mus_musculusHsd3b1ENSMUSG00000027871
mus_musculusHsd3b5ENSMUSG00000038092
mus_musculusHsd3b3ENSMUSG00000062410
mus_musculusHsd3b2ENSMUSG00000063730
mus_musculusHsd3b9ENSMUSG00000090817
mus_musculusHsd3b4ENSMUSG00000095143
mus_musculusHsd3b8ENSMUSG00000095388
rattus_norvegicusHsd3b5ENSRNOG00000019417
rattus_norvegicusHsd3b2ENSRNOG00000019441
rattus_norvegicusHsd3b5-ps1ENSRNOG00000070670
rattus_norvegicusHsd3b1ENSRNOG00000080702
caenorhabditis_elegansWBGENE00022498
caenorhabditis_elegansWBGENE00022616

Paralogs (10): TGDS (ENSG00000088451), HSD3B7 (ENSG00000099377), GFUS (ENSG00000104522), GMDS (ENSG00000112699), UXS1 (ENSG00000115652), GALE (ENSG00000117308), NSDHL (ENSG00000147383), SDR42E2 (ENSG00000183921), SDR42E1 (ENSG00000184860), HSD3B2 (ENSG00000203859)

Protein

Protein identifiers

3 beta-hydroxysteroid dehydrogenase/Delta 5–>4-isomerase type 1 — P14060 (reviewed: P14060)

Alternative names: 3 beta-hydroxysteroid dehydrogenase/Delta 5–>4-isomerase type I, 3-beta-hydroxy-5-ene steroid dehydrogenase, 3-beta-hydroxy-Delta(5)-steroid dehydrogenase, 3-beta-hydroxysteroid 3-dehydrogenase, Delta-5-3-ketosteroid isomerase, Dihydrotestosterone oxidoreductase, Steroid Delta-isomerase, Trophoblast antigen FDO161G

All UniProt accessions (2): E9PRN7, P14060

UniProt curated annotations — full annotation on UniProt →

Function. A bifunctional enzyme responsible for the oxidation and isomerization of 3beta-hydroxy-Delta(5)-steroid precursors to 3-oxo-Delta(4)-steroids, an essential step in steroid hormone biosynthesis. Specifically catalyzes the conversion of pregnenolone to progesterone, 17alpha-hydroxypregnenolone to 17alpha-hydroxyprogesterone, dehydroepiandrosterone (DHEA) to 4-androstenedione, and androstenediol to testosterone. Additionally, catalyzes the interconversion between 3beta-hydroxy and 3-oxo-5alpha-androstane steroids controlling the bioavalability of the active forms. Specifically converts dihydrotestosterone to its inactive form 5alpha-androstanediol, that does not bind androgen receptor/AR. Also converts androstanedione, a precursor of testosterone and estrone, to epiandrosterone. Expected to use NAD(+) as preferred electron donor for the 3beta-hydroxy-steroid dehydrogenase activity and NADPH for the 3-ketosteroid reductase activity.

Subcellular location. Endoplasmic reticulum membrane. Mitochondrion membrane.

Tissue specificity. Placenta and skin. Predominantly expressed in mammary gland tissue.

Pathway. Steroid hormone biosynthesis. Steroid metabolism.

Similarity. Belongs to the 3-beta-HSD family.

RefSeq proteins (2): NP_000853, NP_001315544 (=MANE)

Domains & families (InterPro)

IDNameType
IPR0022253Beta_OHSteriod_DH/EstaseDomain
IPR036291NAD(P)-bd_dom_sfHomologous_superfamily
IPR050177Lipid_A_modif_metabolic_enzFamily

Pfam: PF01073

Enzyme classification (BRENDA):

  • EC 1.1.1.145 — 3beta-hydroxy-DELTA5-steroid dehydrogenase (BRENDA: 24 organisms, 157 substrates, 162 inhibitors, 249 Km, 139 kcat entries)
  • EC 5.3.3.1 — steroid DELTA-isomerase (BRENDA: 15 organisms, 48 substrates, 67 inhibitors, 98 Km, 86 kcat entries)

Substrate kinetics (BRENDA)

96 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

SubstrateKm (mM)Measurements
DEHYDROEPIANDROSTERONE0.0001–0.241966
5-ANDROSTENE-3,17-DIONE0.0001–0.54865
NAD+—43
PREGNENOLONE—21
NADH0.0025–0.1068
ANDROSTENE-3,17-DIONE0.023–0.07356
DEHYDROEPIANDROSTERONE0.0175–0.08846
5(10)-ESTRENE-3,17-DIONE0.0328–0.2565
5-PREGNENE-3,20-DIONE0.0093–0.0685
16ALPHA-HYDROXY-DEHYDROEPIANDROSTERONE0.004–0.01964
16BETA-HYDROXY-DEHYDROEPIANDROSTERONE0.0014–0.01844
5BETA-PREGNANE-3,20-DIONE0.0029–1.7253
NADP+0.0003–133
17ALPHA-HYDROXYPREGNENOLONE0.0035–0.0182
4-NITROBENZALDEHYDE1.966–132

Catalyzed reactions (Rhea), 12 shown:

  • a 3-oxo-Delta(5)-steroid = a 3-oxo-Delta(4)-steroid (RHEA:14709)
  • 5alpha-androstane-3beta,17beta-diol + NADP(+) = 17beta-hydroxy-5alpha-androstan-3-one + NADPH + H(+) (RHEA:16297)
  • a 3beta-hydroxy-Delta(5)-steroid + NAD(+) = a 3-oxo-Delta(5)-steroid + NADH + H(+) (RHEA:24076)
  • a 3beta-hydroxysteroid + NADP(+) = a 3-oxosteroid + NADPH + H(+) (RHEA:34787)
  • 5alpha-androstane-3beta,17beta-diol + NAD(+) = 17beta-hydroxy-5alpha-androstan-3-one + NADH + H(+) (RHEA:42184)
  • pregnenolone + NAD(+) = pregn-5-ene-3,20-dione + NADH + H(+) (RHEA:43924)
  • pregn-5-ene-3,20-dione = progesterone (RHEA:43928)
  • 3beta-hydroxyandrost-5-en-17-one + NAD(+) = androst-5-ene-3,17-dione + NADH + H(+) (RHEA:43932)
  • androst-5-ene-3,17-dione = androst-4-ene-3,17-dione (RHEA:43936)
  • 3beta-hydroxy-5alpha-androstan-17-one + NADP(+) = 5alpha-androstan-3,17-dione + NADPH + H(+) (RHEA:56916)
  • androst-5-en-3beta,17beta-diol + NAD(+) = 17beta-hydroxy-androst-5-en-3-one + NADH + H(+) (RHEA:56932)
  • 17beta-hydroxy-androst-5-en-3-one = testosterone (RHEA:56936)

UniProt features (13 total): sequence variant 6, binding site 3, initiator methionine 1, chain 1, transmembrane region 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-P14060-F194.030.86

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 159 (proton donor)

Ligand- & substrate-binding residues (3): 10–15; 155; 159

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

IDPathway
R-HSA-193048Androgen biosynthesis
R-HSA-193993Mineralocorticoid biosynthesis
R-HSA-194002Glucocorticoid biosynthesis
R-HSA-1430728Metabolism
R-HSA-196071Metabolism of steroid hormones
R-HSA-556833Metabolism of lipids
R-HSA-8957322Metabolism of steroids

MSigDB gene sets: 136 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_UP, SHEPARD_BMYB_MORPHOLINO_UP, GOBP_C21_STEROID_HORMONE_METABOLIC_PROCESS, GOBP_REGULATION_OF_HORMONE_LEVELS, RIZKI_TUMOR_INVASIVENESS_3D_DN, GOBP_KETONE_METABOLIC_PROCESS, KORKOLA_CHORIOCARCINOMA, GOMF_STEROID_DEHYDROGENASE_ACTIVITY_ACTING_ON_THE_CH_OH_GROUP_OF_DONORS_NAD_OR_NADP_AS_ACCEPTOR, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, GOBP_ANDROGEN_BIOSYNTHETIC_PROCESS, UEDA_PERIFERAL_CLOCK, GOBP_HORMONE_BIOSYNTHETIC_PROCESS, ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_DN, FUJIWARA_PARK2_HEPATOCYTE_PROLIFERATION_UP, GOBP_STEROID_BIOSYNTHETIC_PROCESS

GO Biological Process (7): steroid biosynthetic process (GO:0006694), progesterone biosynthetic process (GO:0006701), androgen biosynthetic process (GO:0006702), estrogen biosynthetic process (GO:0006703), C21-steroid hormone metabolic process (GO:0008207), lipid metabolic process (GO:0006629), steroid metabolic process (GO:0008202)

GO Molecular Function (9): 3-beta-hydroxysteroid 3-dehydrogenase (NADP+) activity (GO:0000253), 3-beta-hydroxy-Delta5-steroid dehydrogenase (NAD+) activity (GO:0003854), steroid Delta-isomerase activity (GO:0004769), oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor (GO:0016616), 5-alpha-androstane-3-beta,17-beta-diol dehydrogenase (NADP+) activity (GO:0047024), catalytic activity (GO:0003824), protein binding (GO:0005515), oxidoreductase activity (GO:0016491), isomerase activity (GO:0016853)

GO Cellular Component (14): nucleolus (GO:0005730), cytoplasm (GO:0005737), mitochondrial inner membrane (GO:0005743), mitochondrial intermembrane space (GO:0005758), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), cilium (GO:0005929), microtubule cytoskeleton (GO:0015630), smooth endoplasmic reticulum membrane (GO:0030868), ciliary transition zone (GO:0035869), intercellular bridge (GO:0045171), mitochondrion (GO:0005739), membrane (GO:0016020), mitochondrial membrane (GO:0031966)

Reactome top-level categories

Rollup of top-4 pathways:

CategoryPathways
Metabolism of steroid hormones3
Metabolism of steroids1
Metabolism1
Metabolism of lipids1

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
cellular anatomical structure4
steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor3
steroid metabolic process2
hormone biosynthetic process2
steroid hormone biosynthetic process2
catalytic activity2
mitochondrial envelope2
cytoplasm2
intracellular membrane-bounded organelle2
organelle membrane2
lipid biosynthetic process1
C21-steroid hormone biosynthetic process1
ketone biosynthetic process1
progesterone metabolic process1
olefinic compound biosynthetic process1
androgen metabolic process1
estrogen metabolic process1
hormone metabolic process1
primary metabolic process1
lipid metabolic process1
intramolecular oxidoreductase activity, transposing C=C bonds1
oxidoreductase activity, acting on CH-OH group of donors1
molecular_function1
binding1
nuclear lumen1
intracellular membraneless organelle1
intracellular anatomical structure1
organelle inner membrane1
mitochondrial membrane1
organelle envelope lumen1
endomembrane system1
nuclear outer membrane-endoplasmic reticulum membrane network1
endoplasmic reticulum subcompartment1
intraciliary transport particle1
membrane-bounded organelle1
plasma membrane bounded cell projection1
cytoskeleton1
endoplasmic reticulum membrane1
smooth endoplasmic reticulum1
bounding membrane of organelle1

Protein interactions and networks

STRING

3241 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
HSD3B1CYP11A1P05108972
HSD3B1CYP17A1P05093949
HSD3B1STARP49675896
HSD3B1DHRS11Q6UWP2882
HSD3B1HSD17B1P14061876
HSD3B1CYP19A1P11511861
HSD3B1HSD17B3P37058839
HSD3B1LHCGRP22888809
HSD3B1CYP11B1P15538793
HSD3B1CYP21A2P04033742
HSD3B1CYP11B2P19099735
HSD3B1FSHRP23945734
HSD3B1SRD5A1P18405731
HSD3B1INSL3P51460728
HSD3B1SULT2A1Q06520717

IntAct

31 interactions, top by confidence:

ABTypeScore
HSD3B1AQP6psi-mi:“MI:0915”(physical association)0.560
HSD3B1TMEM14Bpsi-mi:“MI:0915”(physical association)0.560
HSD3B1SLC16A13psi-mi:“MI:0915”(physical association)0.560
CALRHSD3B1psi-mi:“MI:0915”(physical association)0.560
DLSTHSD3B1psi-mi:“MI:0915”(physical association)0.560
HSD3B1FGFR3psi-mi:“MI:0915”(physical association)0.560
HSD3B1GSNpsi-mi:“MI:0915”(physical association)0.560
HSD3B1NEK7psi-mi:“MI:0915”(physical association)0.560
HSD3B2NARS1psi-mi:“MI:0914”(association)0.530
HSD3B1UGGT1psi-mi:“MI:0915”(physical association)0.400
HSD3B1H2BC9psi-mi:“MI:0915”(physical association)0.400
HSD3B1EGFRpsi-mi:“MI:2364”(proximity)0.270
HSD3B1PTENpsi-mi:“MI:2364”(proximity)0.270
HSD3B1AQP6psi-mi:“MI:0915”(physical association)0.000
HSD3B1TMEM14Bpsi-mi:“MI:0915”(physical association)0.000
HSD3B1SLC16A13psi-mi:“MI:0915”(physical association)0.000

BioGRID (9): HSD3B1 (Affinity Capture-MS), HSD3B1 (Two-hybrid), HSD3B1 (Two-hybrid), HSD3B1 (Two-hybrid), UGGT1 (Proximity Label-MS), HIST1H2BH (Proximity Label-MS), HSD3B1 (Affinity Capture-MS), HSD3B1 (Affinity Capture-MS), HSD3B1 (Affinity Capture-MS)

ESM2 similar proteins: A3R052, A8DZE7, A8E5C5, O35296, O35469, O46516, O88736, P0CB81, P0CB82, P14060, P14893, P22071, P22072, P24815, P26149, P26150, P26439, P27364, P27365, P56937, Q0IH28, Q0IH73, Q0MQB3, Q0MQB4, Q0VFE7, Q15738, Q16795, Q32L94, Q3ZBE9, Q4R7R1, Q566S6, Q5IFP1, Q5PPL3, Q5R6U1, Q5RJY4, Q60555, Q61694, Q61767, Q62878, Q62904

Diamond homologs: A0A7H0DNE2, A4TSC8, A6NKP2, A7FCU3, A9R683, B1JQW4, B2FI29, B2JYP2, C0Q1V2, C0QZ84, C4K8I6, O35048, O35296, O35469, O46516, O57245, P14060, P14893, P21097, P22071, P22072, P24815, P26149, P26150, P26439, P26670, P27364, P27365, P33794, P9WQP6, P9WQP7, Q1C276, Q1CD11, Q31FG4, Q57IC3, Q5IFP1, Q60555, Q61694, Q61767, Q62878

SIGNOR signaling

5 interactions.

AEffectBMechanism
HSD3B1“up-regulates quantity”progesterone“chemical modification”
HSD3B1“up-regulates quantity”17alpha-hydroxyprogesterone“chemical modification”
HSD3B1“up-regulates quantity”androst-4-ene-3,17-dione“chemical modification”
Corticotropin“up-regulates quantity”HSD3B1
HSD3B1“up-regulates quantity”testosterone“chemical modification”

Disease & clinical

Clinical variants and AI predictions

ClinVar

74 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic0
Uncertain significance60
Likely benign10
Benign1

Top pathogenic / likely-pathogenic (0)

SpliceAI

533 predictions. Top by Δscore:

VariantEffectΔscore
1:119507617:TTCTA:Tdonor_gain1.0000
1:119507619:CTA:Cdonor_gain1.0000
1:119507620:TA:Tdonor_gain1.0000
1:119507621:AGT:Adonor_loss1.0000
1:119507622:G:GGdonor_gain1.0000
1:119507622:G:Tdonor_loss1.0000
1:119507623:T:Adonor_loss1.0000
1:119511664:AAAG:Adonor_gain1.0000
1:119511665:AAGG:Adonor_loss1.0000
1:119511666:AG:Adonor_loss1.0000
1:119511667:GG:Gdonor_loss1.0000
1:119511668:G:Tdonor_loss1.0000
1:119507612:G:GTdonor_gain0.9900
1:119507618:TCTA:Tdonor_gain0.9900
1:119507625:A:AGdonor_gain0.9900
1:119507626:G:GGdonor_gain0.9900
1:119511501:A:AGacceptor_gain0.9900
1:119511502:G:GAacceptor_gain0.9900
1:119511502:GA:Gacceptor_gain0.9900
1:119511502:GAA:Gacceptor_gain0.9900
1:119513826:ATG:Aacceptor_gain0.9900
1:119513828:G:Aacceptor_gain0.9900
1:119507624:AA:Adonor_loss0.9800
1:119511498:CACA:Cacceptor_loss0.9800
1:119511499:ACAG:Aacceptor_loss0.9800
1:119511500:CA:Cacceptor_loss0.9800
1:119511501:A:ACacceptor_loss0.9800
1:119511580:G:GTdonor_gain0.9800
1:119513827:T:TAacceptor_gain0.9800
1:119513831:CAG:Cacceptor_loss0.9800

AlphaMissense

2433 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
1:119513893:A:CS124R0.993
1:119513895:T:AS124R0.993
1:119513895:T:GS124R0.993
1:119514000:A:CK159N0.991
1:119514000:A:TK159N0.991
1:119513995:A:CS158R0.989
1:119513997:C:AS158R0.989
1:119513997:C:GS158R0.989
1:119513894:G:TS124I0.986
1:119513896:A:CS125R0.986
1:119513898:C:AS125R0.986
1:119513898:C:GS125R0.986
1:119514207:T:AN228K0.985
1:119514207:T:GN228K0.985
1:119513897:G:TS125I0.982
1:119511660:T:AN101K0.981
1:119511660:T:GN101K0.981
1:119513999:A:TK159I0.981
1:119514080:G:CR186P0.981
1:119514295:G:CD258H0.978
1:119507516:T:CF14L0.977
1:119507518:T:AF14L0.977
1:119507518:T:GF14L0.977
1:119514098:G:TG192V0.974
1:119514568:G:CA349P0.972
1:119513859:T:GC112W0.970
1:119513986:T:CY155H0.970
1:119514482:T:AV320D0.969
1:119514079:C:GR186G0.968
1:119514296:A:TD258V0.968

dbSNP variants (sampled 300 via entrez): RS1000301714 (1:119509878 A>C), RS1000327493 (1:119510236 G>T), RS1000381321 (1:119510563 C>T), RS1000577488 (1:119511571 G>T), RS1001237880 (1:119510793 GCAGAGGTGTGATCTTGGCTCACTGC>G), RS1001361958 (1:119510937 G>C,T), RS1001493847 (1:119505252 T>G), RS1001527675 (1:119509481 C>T), RS1001647666 (1:119514810 G>A,T), RS1001659066 (1:119515155 G>A,T), RS1001809473 (1:119506938 A>T), RS1001830779 (1:119506624 C>A), RS1001912217 (1:119508634 T>C), RS1001984557 (1:119513827 T>G), RS1003081618 (1:119511772 G>A,T)

Disease associations

OMIM: gene MIM:109715 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

StudyTraitp-value
GCST002875_155Diisocyanate-induced asthma1.000000e-06

EFO canonical traits (1, from GWAS)

EFO IDTrait name
EFO:0006995response to diisocyanate

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1958 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 51,247 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

MoleculeNamePhasePatents
CHEMBL710FINASTERIDE451,247

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

VariantTypeLevelDrugsPhenotypes
rs1047303Efficacy3glucocorticoidsAsthma

PharmGKB variants

1 variants.

VariantGenesLevelScore#Clin annotsDrugs
rs1047303HSD3B133.251glucocorticoids

Binding affinities (BindingDB)

94 measured of 95 human assays (95 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

LigandMeasureValuePatent
(6S)-2-(3,5-difluoro-4-hydroxyphenyl)-6-ethyl-6-methyl-7,8-dihydroquinolin-5-oneIC500.7 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(2,5-difluoro-4-hydroxyphenyl)-6,6-dimethyl-7,8-dihydroquinolin-5-oneIC501 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6,6-dimethyl-7,8-dihydroquinolin-5-oneIC501.4 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6,6-diethyl-7,8-dihydroquinolin-5-oneIC503.8 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)spiro[7,8-dihydroquinoline-6,1’-cyclopropane]-5-oneIC504.8 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
6-benzyl-2-(3,5-difluoro-4-hydroxyphenyl)-7,8-dihydro-6H-quinolin-5-oneIC5010 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3-fluoro-4-hydroxyphenyl)-7,8-dihydro-6H-quinolin-5-oneIC5014 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
(6S)-6-benzyl-2-(3,5-difluoro-4-hydroxyphenyl)-7,8-dihydro-6H-quinolin-5-oneIC5019 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2,6-difluoro-4-(5-methoxy-5-pyridin-3-yl-7,8-dihydro-6H-quinolin-2-yl)phenolIC5025 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3-chloro-4-hydroxyphenyl)-6,6-dimethyl-7,8-dihydroquinolin-5-oneIC5026 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2,6-difluoro-4-(5-methoxy-5-methyl-7,8-dihydro-6H-quinolin-2-yl)phenolIC5038 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6-fluoro-6-methyl-7,8-dihydroquinolin-5-oneIC5042 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2,6-difluoro-4-(5-methoxy-5-propan-2-yl-7,8-dihydro-6H-quinolin-2-yl)phenolIC5045 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3-chloro-5-fluoro-4-hydroxyphenyl)-7,8-dihydro-6H-quinolin-5-oneIC5049 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3-fluoro-4-hydroxyphenyl)-6,6-dimethyl-7,8-dihydroquinolin-5-oneIC5051 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2,6-difluoro-4-(5-phenyl-5-propoxy-7,8-dihydro-6H-quinolin-2-yl)phenolIC5052 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
(6S)-6-benzyl-2-(3,5-difluoro-4-hydroxyphenyl)-6-methyl-7,8-dihydroquinolin-5-oneIC5055 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6-methyl-6-(trifluoromethyl)-7,8-dihydroquinolin-5-oneIC5059 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-7,8-dihydro-6H-quinolin-5-oneIC5062 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6-methyl-7,8-dihydro-6H-quinolin-5-oneIC5064 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3-fluoro-4-hydroxy-5-methylphenyl)-6,6-dimethyl-7,8-dihydroquinolin-5-oneIC5067 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6,6-difluoro-7,8-dihydroquinolin-5-oneIC5068 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-5-pyridin-3-yl-7,8-dihydro-6H-quinolin-5-olIC5068 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
(6S)-6-benzyl-2-(3,5-difluoro-4-hydroxyphenyl)-6-methyl-7,8-dihydroquinolin-5-oneIC5078 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6-methyl-6-(1,1,2,2,2-pentafluoroethyl)-7,8-dihydroquinolin-5-oneIC5078 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6-phenyl-7,8-dihydro-6H-quinolin-5-oneIC5079 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(2,5-difluoro-4-hydroxyphenyl)-7,8-dihydro-6H-quinolin-5-oneIC5083 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6,7,8,9-tetrahydrocyclohepta[b]pyridin-5-oneIC5090 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6-methyl-5-oxo-7,8-dihydroquinoline-6-carbonitrileIC5092 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2,6-difluoro-4-[5-methoxy-5-(1,3-oxazol-2-yl)-7,8-dihydro-6H-quinolin-2-yl]phenolIC50100 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6-ethyl-7,8-dihydro-6H-quinolin-5-oneIC50105 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6,6-dimethyl-7,8-dihydroquinolin-5-oneIC50107 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
(6R)-2-(3,5-difluoro-4-hydroxyphenyl)-6-ethyl-6-methyl-7,8-dihydroquinolin-5-oneIC50110 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(2,3-difluoro-4-hydroxyphenyl)-6,6-dimethyl-7,8-dihydroquinolin-5-oneIC50122 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(2,5-difluoro-4-hydroxyphenyl)spiro[7,8-dihydroquinoline-6,1’-cyclopropane]-5-oneIC50127 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
6-(cyclopropylmethyl)-2-(3,5-difluoro-4-hydroxyphenyl)-7,8-dihydro-6H-quinolin-5-oneIC50130 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2,6-difluoro-4-(5-methoxy-5-pyridin-2-yl-7,8-dihydro-6H-quinolin-2-yl)phenolIC50131 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6-fluoro-7,8-dihydro-6H-quinolin-5-oneIC50149 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
6,6-dimethyl-2-(2,3,5-trifluoro-4-hydroxyphenyl)-7,8-dihydroquinolin-5-oneIC50152 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
(6R)-6-benzyl-2-(3,5-difluoro-4-hydroxyphenyl)-7,8-dihydro-6H-quinolin-5-oneIC50177 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6-methyl-6-(2,2,2-trifluoroethyl)-7,8-dihydroquinolin-5-oneIC50188 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2,6-difluoro-4-(5-methoxy-5,6,7,8-tetrahydroquinolin-2-yl)phenolIC50204 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6-(pyridin-4-ylmethyl)-7,8-dihydro-6H-quinolin-5-oneIC50212 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
7-(3,5-difluoro-4-hydroxyphenyl)-2,3-dihydro-1H-1,8-naphthyridin-4-oneIC50218 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6,6-dimethyl-7H-cyclopenta[b]pyridin-5-oneIC50221 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6-(hydroxymethyl)-6-methyl-7,8-dihydroquinolin-5-oneIC50222 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
5-benzyl-2-(3,5-difluoro-4-hydroxyphenyl)-6,6-dimethyl-7,8-dihydroquinolin-5-olIC50227 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-5-pyridin-2-yl-7,8-dihydro-6H-quinolin-5-olIC50238 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6-(pyridin-3-ylmethyl)-7,8-dihydro-6H-quinolin-5-oneIC50249 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF
2-(3,5-difluoro-4-hydroxyphenyl)-6-(pyridin-2-ylmethyl)-7,8-dihydro-6H-quinolin-5-oneIC50272 nMUS-20250241905: 3-BETA-HSD1 INHIBITORS AND COMPOSITIONS AND USES THEREOF

ChEMBL bioactivities

14 potent at pChembl≥5 of 15 total, top 14 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChemblTypeValueUnitMolecule
8.11Ki7.8nMCHEMBL25516
8.08IC508.3nMCHEMBL24033
8.00Ki10nMCHEMBL280155
7.92Ki12nMCHEMBL297524
7.72Ki19nMCHEMBL25183
6.82IC50150nMCHEMBL24729
6.82Ki150nMCHEMBL24088
6.80Ki160nMCHEMBL283123
6.75Ki180nMCHEMBL3085538
6.72Ki190nMCHEMBL24291
6.72Ki190nMCHEMBL282037
6.31Ki490nMCHEMBL283430
6.29Ki510nMCHEMBL412425
5.80Ki1600nMCHEMBL277224

PubChem BioAssay actives

14 with measured affinity, of 15 total; 14 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

CompoundAssayTypeValueUnit
(1S,9aR,11aS)-N-(3,5-ditert-butylphenyl)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,8,9,9b,10,11-dodecahydrocyclopenta[i]phenanthridine-1-carboxamide3228: Binding affinity for 3-beta-hydroxysteroid dehydrogenaseki0.0078uM
(1S,9aR,11aS)-N-(3,3-dimethylbutyl)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,8,9,9b,10,11-dodecahydrocyclopenta[i]phenanthridine-1-carboxamide3227: Binding affinity on 3 beta-hydroxysteroid dehydrogenaseic500.0083uM
(1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-N-phenyl-1,2,3,3a,3b,4,5,8,9,9b,10,11-dodecahydrocyclopenta[i]phenanthridine-1-carboxamide3228: Binding affinity for 3-beta-hydroxysteroid dehydrogenaseki0.0100uM
methyl (1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,8,9,9b,10,11-dodecahydrocyclopenta[i]phenanthridine-1-carboxylate3228: Binding affinity for 3-beta-hydroxysteroid dehydrogenaseki0.0120uM
(1S,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-6,9a,11a-trimethyl-7-oxo-1,2,3,3a,3b,4,5,8,9,9b,10,11-dodecahydrocyclopenta[i]phenanthridine-1-carboxamide3228: Binding affinity for 3-beta-hydroxysteroid dehydrogenaseki0.0190uM
(1S,9aR,11aS)-9a,11a-dimethyl-7-oxo-N-(2,4,4-trimethylpentan-2-yl)-1,2,3,3a,3b,4,5,8,9,9b,10,11-dodecahydrocyclopenta[i]phenanthridine-1-carboxamide3227: Binding affinity on 3 beta-hydroxysteroid dehydrogenaseic500.1500uM
(1S,9aR,11aS)-N-benzhydryl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,8,9,9b,10,11-dodecahydrocyclopenta[i]phenanthridine-1-carboxamide3228: Binding affinity for 3-beta-hydroxysteroid dehydrogenaseki0.1500uM
(1S,9aR,11aS)-N-(4-chlorophenyl)-N-cyclopentyl-6,9a,11a-trimethyl-7-oxo-1,2,3,3a,3b,4,5,8,9,9b,10,11-dodecahydrocyclopenta[i]phenanthridine-1-carboxamide3228: Binding affinity for 3-beta-hydroxysteroid dehydrogenaseki0.1600uM
2-adamantyl (1S,3aS,3bS,9aR,9bS,11aS)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,8,9,9b,10,11-dodecahydrocyclopenta[i]phenanthridine-1-carboxylate3228: Binding affinity for 3-beta-hydroxysteroid dehydrogenaseki0.1800uM
(1S,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-6-chloro-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,8,9,9b,10,11-dodecahydrocyclopenta[i]phenanthridine-1-carboxamide3228: Binding affinity for 3-beta-hydroxysteroid dehydrogenaseki0.1900uM
(1S,9aR,11aS)-9a,11a-dimethyl-1-(morpholine-4-carbonyl)-1,2,3,3a,3b,4,5,8,9,9b,10,11-dodecahydrocyclopenta[i]phenanthridin-7-one3228: Binding affinity for 3-beta-hydroxysteroid dehydrogenaseki0.1900uM
(1S,9aR,11aS)-6-chloro-N-(4-chlorophenyl)-N-cyclopentyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,8,9,9b,10,11-dodecahydrocyclopenta[i]phenanthridine-1-carboxamide3228: Binding affinity for 3-beta-hydroxysteroid dehydrogenaseki0.4900uM
(1S,9aR,11aS)-N-[bis(4-chlorophenyl)methyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,8,9,9b,10,11-dodecahydrocyclopenta[i]phenanthridine-1-carboxamide3228: Binding affinity for 3-beta-hydroxysteroid dehydrogenaseki0.5100uM
(1S,9aR,11aS)-N-[2-tert-butyl-5-(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,8,9,9b,10,11-dodecahydrocyclopenta[i]phenanthridine-1-carboxamide3228: Binding affinity for 3-beta-hydroxysteroid dehydrogenaseki1.6000uM

CTD chemical–gene interactions

118 total (human), top 30 by PubMed support.

ChemicalActions (top 5)PubMed papers
bisphenol Adecreases activity, increases expression, decreases reaction3
Estradioldecreases activity, increases expression3
Testosteroneaffects cotreatment, increases expression, increases chemical synthesis, decreases expression3
Aflatoxin B1decreases expression, increases expression, decreases reaction3
triphenyl phosphateincreases expression, affects reaction, decreases reaction2
perfluoro-n-nonanoic aciddecreases activity, decreases expression2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamideincreases expression, affects cotreatment2
Fulvestrantdecreases reaction, increases expression, increases methylation2
Ascorbic Acidaffects cotreatment, increases expression, affects binding2
Benzo(a)pyreneincreases methylation, increases mutagenesis2
Diethylstilbestroldecreases activity, decreases expression2
Dithiothreitolincreases activity, decreases activity, decreases reaction2
Pentachlorophenolincreases abundance, increases activity, decreases expression, decreases activity2
Progesteroneincreases chemical synthesis, increases expression2
Tetrachlorodibenzodioxinaffects cotreatment, decreases expression2
8-Bromo Cyclic Adenosine Monophosphatedecreases expression2
Vitamin K 3affects expression, affects binding, affects cotreatment2
cyclopiazonic aciddecreases activity1
STF-31affects cotreatment, decreases reaction, increases expression1
fluorene-9-bisphenoldecreases activity1
perfluorotetradecanoic aciddecreases activity1
perfluorotridecanoic aciddecreases activity1
3,3’-dimethylbisphenol Adecreases activity1
dioxybenzonedecreases activity1
deoxynivalenoldecreases activity1
dichlonedecreases activity1
2,4,5,2’,5’-pentachlorobiphenylincreases expression1
isoamyl salicylatedecreases activity1
ferbamdecreases activity1
ascorbate-2-phosphateaffects cotreatment, increases expression, affects binding1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay IDTypeDescriptionSource paper
CHEMBL615301BindingBinding affinity on 3 beta-hydroxysteroid dehydrogenasePharmacological options in the treatment of benign prostatic hyperplasia. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 80

This page pulls from 80 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomereactomeparentrefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot